Acamptas 333 Tablet (Acamprosate 333mg)

What is Acamptas 333 Tablet (Acamprosate 333mg)?

Acamptas 333 Tablet is a branded formulation containing 333mg of acamprosate calcium, a medication approved to help individuals maintain abstinence from alcohol after completing detoxification. It works by stabilizing chemical signaling in the brain disrupted by long-term alcohol use, particularly balancing glutamate and GABA neurotransmitters. Unlike sedative-based treatments, Acamptas does not target withdrawal symptoms directly but supports long-term recovery by reducing cravings and the urge to drink. It is intended for oral use, typically taken three times daily, and is most effective when combined with psychosocial support such as counseling or behavioral therapy.

Key features

• Active Ingredient — Contains acamprosate calcium 333mg per tablet.
• Prescription Use — Designed for long-term management of alcohol dependence.
• Non-Addictive — Does not cause dependence or sedation.
• Dosage Form — Film-coated tablet for oral administration.
• Targeted Action — Helps normalize brain chemistry post-alcohol use.
• Support Therapy — Used alongside counseling and support programs.
• Stability — Shelf-stable under recommended storage conditions.

Who is Acamptas 333 Tablet (Acamprosate 333mg) for?

This medication is intended for adults diagnosed with alcohol use disorder who have already stopped drinking and aim to maintain sobriety. It is not for use during active alcohol withdrawal or in individuals with severe kidney impairment. Patients should be committed to abstinence and engaged in recovery programs for optimal results. A healthcare provider must evaluate suitability based on medical history and treatment goals.

How does Acamptas 333 Tablet (Acamprosate 333mg) compare?

Compared to other alcohol dependence medications like naltrexone or disulfiram, Acamptas offers a different mechanism—focusing on brain chemistry normalization rather than blocking alcohol effects or creating aversion. It is non-sedating and non-addictive, making it suitable for long-term use. While naltrexone may reduce drinking urges through opioid receptor blockade, acamprosate specifically targets post-acute withdrawal symptoms. It compares closely to generic acamprosate tablets in efficacy but may differ in formulation consistency or availability. Unlike benzodiazepines used in detox, it is not indicated for withdrawal management.